Advertisement

Drug interactions with oral anticoagulants in German nursing home residents: comparison between vitamin K antagonists and non-vitamin K antagonist oral anticoagulants based on two nested case–control studies

  • Kathrin JobskiEmail author
  • Falk Hoffmann
  • Stefan Herget-Rosenthal
  • Michael Dörks
Original Paper
  • 139 Downloads

Abstract

Background

Vitamin K antagonists (VKAs) are susceptible to drug–drug interactions. Non-VKA oral anticoagulants (NOACs) have a decreased sensitivity to pharmacokinetic interactions and might be therefore considered superior in patients treated with multiple drugs. The objective of this study was to compare the risk of serious bleeding associated with interacting drugs in German nursing home residents treated with VKA or NOAC.

Methods

Using claims data of new nursing home residents aged ≥ 65 years (2010–2014) we conducted separate nested case–control analyses within two cohorts of patients treated with VKA or NOAC, respectively. Cases were defined as patients hospitalized for serious bleeding. For each case, up to 20 controls were selected by risk-set sampling. Conditional logistic regression was used to obtain confounder-adjusted odds ratios (aORs) and 95% confidence intervals (CI) for the risk of bleeding associated with VKA or NOAC use and interacting drugs compared with the use of the respective oral anticoagulant alone.

Results

Among 127,227 new nursing home residents, 16,804 patients received oral anticoagulation. Based on 372 cases and 7281 matched controls, the highest risk of bleeding in VKA users was observed for the concomitant use of antibiotics (aOR 3.00; CI 2.11–4.27) vs. VKA use alone, followed by non-steroidal anti-inflammatory drugs (1.66; 1.13–2.43). Among 243 NOAC cases and 4776 matched controls, elevated risks for bleeding were observed for the use of heparins (2.05; 1.25–3.36) and platelet inhibitors (1.92; 1.36–2.72).

Conclusions

Concomitant medication needs to be prescribed cautiously and monitored closely in nursing home residents treated with oral anticoagulants.

Graphic Abstract

Keywords

Anticoagulants Drug interactions Risk of bleeding Nursing home residents 

Notes

Acknowledgements

The authors thank the DAK-Gesundheit for providing the data for this study.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Supplementary material

392_2019_1526_MOESM1_ESM.docx (66 kb)
Supplementary material 1 (DOCX 66 kb)

References

  1. 1.
    Barnes GD, Lucas E, Alexander GC, Goldberger ZD (2015) National trends in ambulatory oral anticoagulant use. Am J Med 128:1300–1305.e2.  https://doi.org/10.1016/j.amjmed.2015.05.044 CrossRefGoogle Scholar
  2. 2.
    Loo SY, Dell’Aniello S, Huiart L, Renoux C (2017) Trends in the prescription of novel oral anticoagulants in UK primary care. Br J Clin Pharmacol 83:2096–2106.  https://doi.org/10.1111/bcp.13299 CrossRefGoogle Scholar
  3. 3.
    Gadsbøll K, Staerk L, Fosbøl EL et al (2017) Increased use of oral anticoagulants in patients with atrial fibrillation: temporal trends from 2005 to 2015 in Denmark. Eur Heart J 38:899–906.  https://doi.org/10.1093/eurheartj/ehw658 Google Scholar
  4. 4.
    Hein L, Wille H (2018) Antithrombotika und Antihämorrhagika. Arzneiverordnungs-report 2018. Springer, Berlin, pp 401–421CrossRefGoogle Scholar
  5. 5.
    Shehab N, Lovegrove MC, Geller AI et al (2016) US emergency department visits for outpatient adverse drug events, 2013–2014. JAMA 316:2115.  https://doi.org/10.1001/jama.2016.16201 CrossRefGoogle Scholar
  6. 6.
    Vazquez SR (2018) Drug-drug interactions in an era of multiple anticoagulants: a focus on clinically relevant drug interactions. Blood 132:2230–2239.  https://doi.org/10.1182/blood-2018-06-848747 CrossRefGoogle Scholar
  7. 7.
    Pharma GmbH MEDA, Co KG (2018) Marcumar. Summary of products characteristics. Fachinfo-Service, FrankfurtGoogle Scholar
  8. 8.
    Squibb Bristol-Myers (2017) Coumadin. Summary of products characteristics. Fachinfo-Service, FrankfurtGoogle Scholar
  9. 9.
    Snyder BD, Polasek TM, Doogue MP (2012) Drug interactions: principles and practice. Aust Prescr.  https://doi.org/10.18773/austprescr.2012.037 Google Scholar
  10. 10.
    Gelosa P, Castiglioni L, Tenconi M et al (2018) Pharmacokinetic drug interactions of the non-vitamin K antagonist oral anticoagulants (NOACs). Pharmacol Res 135:60–79.  https://doi.org/10.1016/j.phrs.2018.07.016 CrossRefGoogle Scholar
  11. 11.
    Zotz RB, Weißbach L (2017) Monitoring of NOAC. Med Klin Intensivmed Notfmed 112:92–98.  https://doi.org/10.1007/s00063-016-0249-6 CrossRefGoogle Scholar
  12. 12.
    Stöllberger C (2017) Drug interactions with new oral anticoagulants in elderly patients. Expert Rev Clin Pharmacol.  https://doi.org/10.1080/17512433.2017.1370369 Google Scholar
  13. 13.
    Hohnloser SH, Basic E, Nabauer M (2019) Uptake in antithrombotic treatment and its association with stroke incidence in atrial fibrillation: insights from a large German claims database. Clin Res Cardiol.  https://doi.org/10.1007/s00392-019-01437-7 Google Scholar
  14. 14.
    Reardon G, Pandya N, Nutescu EA et al (2013) Incidence of venous thromboembolism in nursing home residents. J Am Med Dir Assoc 14:578–584.  https://doi.org/10.1016/j.jamda.2013.02.003 CrossRefGoogle Scholar
  15. 15.
    Sinnaeve PR, Brueckmann M, Clemens A et al (2012) Stroke prevention in elderly patients with atrial fibrillation: challenges for anticoagulation. J Intern Med 271:15–24.  https://doi.org/10.1111/j.1365-2796.2011.02464.x CrossRefGoogle Scholar
  16. 16.
    Jobski K, Hoffmann F, Herget-Rosenthal S, Dörks M (2018) Use of oral anticoagulants in German nursing home residents: drug use patterns and predictors for treatment choice. Br J Clin Pharmacol 84:590–601.  https://doi.org/10.1111/bcp.13474 CrossRefGoogle Scholar
  17. 17.
    Dörks M, Herget-Rosenthal S, Schmiemann G, Hoffmann F (2016) Polypharmacy and renal failure in nursing home residents: results of the inappropriate Medication in Patients with Renal Insufficiency in Nursing Homes (IMREN) Study. Drugs Aging 33:45–51.  https://doi.org/10.1007/s40266-015-0333-2 CrossRefGoogle Scholar
  18. 18.
    Palareti G, Cosmi B (2009) Bleeding with anticoagulation therapy—who is at risk, and how best to identify such patients. Thromb Haemost.  https://doi.org/10.1160/TH08-11-0730 Google Scholar
  19. 19.
    Wacholder S, Silverman DT, McLaughlin JK, Mandel JS (1992) Selection of controls in case-control studies. III. Design options. Am J Epidemiol 135:1042–1050CrossRefGoogle Scholar
  20. 20.
    Jobski K, Behr S, Garbe E (2011) Drug interactions with phenprocoumon and the risk of serious haemorrhage: a nested case–control study in a large population-based German database. Eur J Clin Pharmacol 67:941–951.  https://doi.org/10.1007/s00228-011-1031-6 CrossRefGoogle Scholar
  21. 21.
    Abbas S, Ihle P, Harder S, Schubert I (2014) Risk of bleeding and antibiotic use in patients receiving continuous phenprocoumon therapy. Thromb Haemost 111:912–922.  https://doi.org/10.1160/TH13-09-0723 CrossRefGoogle Scholar
  22. 22.
    Chang SH, Chou IJ, Yeh YH et al (2017) Association between use of non–vitamin K oral anticoagulants with and without concurrent medications and risk of major bleeding in nonvalvular atrial fibrillation. JAMA J Am Med Assoc 318:1250–1259.  https://doi.org/10.1001/jama.2017.13883 CrossRefGoogle Scholar
  23. 23.
    Büscher A, Wingenfeld K, Schaeffer D (2011) Determining eligibility for long-term care-lessons from Germany. Int J Integr Care 11:e019.  https://doi.org/10.5334/ijic.584 Google Scholar
  24. 24.
    Langan SM, Schmidt SA, Wing K et al (2018) The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE). BMJ 363:k3532.  https://doi.org/10.1136/bmj.k3532 CrossRefGoogle Scholar
  25. 25.
    Ihle P, Krueger K, Schubert I et al (2019) Comparison of different strategies to measure medication adherence via claims data in patients with chronic heart failure. Clin Pharmacol Ther.  https://doi.org/10.1002/cpt.1378 Google Scholar
  26. 26.
    Connolly SJ, Ezekowitz MD, Yusuf S et al (2009) Dabigatran versus warfarin in patients with atrial fibrillation.[Erratum appears in N Engl J Med. 2010 Nov 4;363(19):1877]. N Engl J Med.  https://doi.org/10.1056/NEJMoa0905561 Google Scholar
  27. 27.
    Patel MR, Mahaffey KW, Garg J et al (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365:883–891.  https://doi.org/10.1056/NEJMoa1009638 CrossRefGoogle Scholar
  28. 28.
    Granger CB, Alexander JH, McMurray JJV et al (2011) Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365:981–992.  https://doi.org/10.1056/NEJMoa1107039 CrossRefGoogle Scholar
  29. 29.
    Agnelli G, Buller HR, Cohen A et al (2013) Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 369:799–808.  https://doi.org/10.1056/NEJMoa1302507 CrossRefGoogle Scholar
  30. 30.
    Investigators EINSTEIN, Bauersachs R, Berkowitz SD et al (2010) Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 363:2499–2510.  https://doi.org/10.1056/NEJMoa1007903 CrossRefGoogle Scholar
  31. 31.
    EINSTEIN–PE Investigators, Büller HR, Prins MH et al (2012) Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 366:1287–1297.  https://doi.org/10.1056/nejmoa1113572 CrossRefGoogle Scholar
  32. 32.
    Sjögren V, Byström B, Renlund H et al (2017) Non-Vitamin K oral anticoagulants are non-inferior for stroke prevention but cause fewer major bleedings than well-managed warfarin: a retrospective register study. PLoS One.  https://doi.org/10.1371/journal.pone.0181000 Google Scholar
  33. 33.
    Yao X, Abraham NS, Sangaralingham LR et al (2016) Effectiveness and safety of dabigatran, rivaroxaban, and apixaban versus warfarin in nonvalvular atrial fibrillation. J Am Heart Assoc.  https://doi.org/10.1161/JAHA.116.003725 Google Scholar
  34. 34.
    Larsen TB, Skjøth F, Nielsen PB et al (2016) Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ.  https://doi.org/10.1136/bmj.i3189 Google Scholar
  35. 35.
    Lip GYH, Keshishian A, Kamble S et al (2016) Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin: a propensity score matched analysis. Thromb Haemost.  https://doi.org/10.1160/TH16-05-0403 Google Scholar
  36. 36.
    Ujeyl M, Köster I, Wille H et al (2018) Comparative risks of bleeding, ischemic stroke and mortality with direct oral anticoagulants versus phenprocoumon in patients with atrial fibrillation. Eur J Clin Pharmacol.  https://doi.org/10.1007/s00228-018-2504-7 Google Scholar
  37. 37.
    Hohnloser SH, Basic E, Nabauer M (2017) Comparative risk of major bleeding with new oral anticoagulants (NOACs) and phenprocoumon in patients with atrial fibrillation: a post-marketing surveillance study. Clin Res Cardiol.  https://doi.org/10.1007/s00392-017-1098-x Google Scholar
  38. 38.
    Takach Lapner S, Cohen N, Kearon C (2014) Influence of sex on risk of bleeding in anticoagulated patients: a systematic review and meta-analysis. J Thromb Haemost.  https://doi.org/10.1111/jth.12529 Google Scholar
  39. 39.
    Floyd CN, Ferro A (2017) Indications for anticoagulant and antiplatelet combined therapy. BMJ.  https://doi.org/10.1136/bmj.j3782 Google Scholar
  40. 40.
    Hansen ML, Sørensen R, Clausen MT et al (2010) Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med.  https://doi.org/10.1001/archinternmed.2010.271 Google Scholar
  41. 41.
    Oldgren J, Wallentin L, Alexander JH et al (2013) New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysis. Eur Heart J 34:1670–1680.  https://doi.org/10.1093/eurheartj/eht049 CrossRefGoogle Scholar
  42. 42.
    Duerschmied D, Brachmann J, Darius H et al (2018) Antithrombotic therapy in patients with non-valvular atrial fibrillation undergoing percutaneous coronary intervention: should we change our practice after the PIONEER AF-PCI and RE-DUAL PCI trials? Clin Res Cardiol.  https://doi.org/10.1007/s00392-018-1242-2 Google Scholar
  43. 43.
    Bjarnason I, Scarpignato C, Holmgren E et al (2018) Mechanisms of damage to the gastrointestinal tract from nonsteroidal anti-inflammatory drugs. Gastroenterology 154:500–514.  https://doi.org/10.1053/j.gastro.2017.10.049 CrossRefGoogle Scholar
  44. 44.
    Ray WA, Chung CP, Murray KT et al (2018) Association of oral anticoagulants and proton pump inhibitor cotherapy with hospitalization for upper gastrointestinal tract bleeding. JAMA 320:2221.  https://doi.org/10.1001/jama.2018.17242 CrossRefGoogle Scholar
  45. 45.
    Henriksen DP, Stage TB, Hansen MR et al (2015) The potential drug–drug interaction between proton pump inhibitors and warfarin. Pharmacoepidemiol Drug Saf.  https://doi.org/10.1002/pds.3881 Google Scholar
  46. 46.
    Jobski K, Schmedt N, Kollhorst B et al (2017) Characteristics and drug use patterns of older antidepressant initiators in Germany. Eur J Clin Pharmacol 73:105–113.  https://doi.org/10.1007/s00228-016-2145-7 CrossRefGoogle Scholar
  47. 47.
    Bouillon K, Bertrand M, Boudali L et al (2016) Short-term risk of bleeding during heparin bridging at initiation of vitamin K antagonist therapy in more than 90 000 patients with nonvalvular atrial fibrillation managed in outpatient care. J Am Heart Assoc 1:1.  https://doi.org/10.1161/JAHA.116.004065 Google Scholar
  48. 48.
    Siegal D, Yudin J, Kaatz S et al (2012) Periprocedural heparin bridging in patients receiving vitamin K antagonists: systematic review and meta-analysis of bleeding and thromboembolic rates. Circulation.  https://doi.org/10.1161/CIRCULATIONAHA.112.105221 Google Scholar
  49. 49.
    Bauersachs R, Agnelli G, Gitt AK et al (2017) The role of heparin lead-in in the real-world management of acute venous thromboembolism: the PREFER in VTE registry. Thromb Res 157:181–188.  https://doi.org/10.1016/j.thromres.2017.07.029 CrossRefGoogle Scholar
  50. 50.
    Holm J, Lindh JD, Andersson ML, Mannheimer B (2017) The effect of amiodarone on warfarin anticoagulation: a register-based nationwide cohort study involving the Swedish population. J Thromb Haemost.  https://doi.org/10.1111/jth.13614 Google Scholar
  51. 51.
    Lochner S, Kirch W, Schindler C (2012) Managing hypertension among nursing-home residents and community-dwelling elderly in Germany: a comparative pharmacoepidemiological study. Eur J Clin Pharmacol.  https://doi.org/10.1007/s00228-011-1195-0 Google Scholar
  52. 52.
    Hughes CM, Goldie R (2009) “I just take what i am given”: adherence and resident involvement in decision making on medicines in nursing homes for older people: a qualitative survey. Drugs Aging.  https://doi.org/10.2165/00002512-200926060-00007 Google Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Health Services ResearchCarl von Ossietzky University OldenburgOldenburgGermany
  2. 2.Department of MedicineRotes Kreuz HospitalBremenGermany

Personalised recommendations